Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 3
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.
Charlier C, Perrodeau É, Leclercq A, Cazenave B, Pilmis B, Henry B, Lopes A, Maury MM, Moura A, Goffinet F, Dieye HB, Thouvenot P, Ungeheuer MN, Tourdjman M, Goulet V, de Valk H, Lortholary O, Ravaud P, Lecuit M; MONALISA study group. Charlier C, et al. Lancet Infect Dis. 2017 May;17(5):510-519. doi: 10.1016/S1473-3099(16)30521-7. Epub 2017 Jan 28. Lancet Infect Dis. 2017. PMID: 28139432 Free article.
Primary immunodeficiency-related bronchiectasis in adults: comparison with bronchiectasis of other etiologies in a French reference center.
Goussault H, Salvator H, Catherinot E, Chabi ML, Tcherakian C, Chabrol A, Didier M, Rivaud E, Fischer A, Suarez F, Hermine O, Lanternier F, Lortholary O, Mahlaoui N, Devillier P, Couderc LJ. Goussault H, et al. Respir Res. 2019 Dec 4;20(1):275. doi: 10.1186/s12931-019-1242-4. Respir Res. 2019. PMID: 31801528 Free PMC article.
Low income and outcome in idiopathic pulmonary fibrosis: An association to uncover.
Sesé L, Caliez J, Annesi-Maesano I, Cottin V, Pesce G, Didier M, Carton Z, Israel-Biet D, Crestani B, Dudoret SG, Cadranel J, Wallaert B, Tazi A, Maître B, Prévot G, Marchand-Adam S, Hirschi S, Dury S, Giraud V, Gondouin A, Bonniaud P, Traclet J, Juvin K, Borie R, Bernaudin JF, Valeyre D, Cavalin C, Nunes H; COFI collaborators. Sesé L, et al. Respir Med. 2021 Jul;183:106415. doi: 10.1016/j.rmed.2021.106415. Epub 2021 Apr 27. Respir Med. 2021. PMID: 33965849
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.
Naccache JM, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, Reynaud-Gaubert M, Bonniaud P, Israël-Biet D, Prévot G, Hirschi S, Lebargy F, Marchand-Adam S, Bautin N, Traclet J, Gomez E, Leroy S, Gagnadoux F, Rivière F, Bergot E, Gondouin A, Blanchard E, Parrot A, Blanc FX, Chabrol A, Dominique S, Gibelin A, Tazi A, Berard L, Brillet PY, Debray MP, Rousseau A, Kerjouan M, Freynet O, Dombret MC, Gamez AS, Nieves A, Beltramo G, Pastré J, Le Borgne-Krams A, Dégot T, Launois C, Plantier L, Wémeau-Stervinou L, Cadranel J, Chenivesse C, Valeyre D, Crestani B, Cottin V, Simon T, Nunes H; EXAFIP investigators and the OrphaLung network. Naccache JM, et al. Lancet Respir Med. 2021 Sep 7:S2213-2600(21)00354-4. doi: 10.1016/S2213-2600(21)00354-4. Online ahead of print. Lancet Respir Med. 2021. PMID: 34506761